Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney as Strategy & Business Advisor. Dr. Phinney brings over 20 years of experience in pharmaceutical R&D and biotech innovation, having held key positions at Abbott, AbbVie, and Solvay Pharmaceuticals.
Dr. Phinney's extensive background includes serving as Chief Scientific Officer at Lakeside Discovery and Senior Director of Partnerships at adMare BioInnovations. She holds a PhD in Biomedical Research and an MBA, with additional executive training from prestigious institutions. The appointment aims to help Defence Therapeutics capitalize on new opportunities emerging from recent scientific advances in antibody-delivered therapeutics.
Defence Therapeutics (OTCQB: DTCFF), azienda biotecnologica specializzata in tecnologie di somministrazione dei farmaci, ha nominato Dr.ssa Amie Phinney come Strategy & Business Advisor. La Dr.ssa Phinney vanta oltre 20 anni di esperienza nella R&S farmaceutica e nell'innovazione biotech, avendo ricoperto ruoli chiave in Abbott, AbbVie e Solvay Pharmaceuticals.
Il suo percorso include incarichi come Chief Scientific Officer presso Lakeside Discovery e Senior Director of Partnerships presso adMare BioInnovations. È in possesso di un dottorato in Ricerca Biomedica e di un MBA, oltre a percorsi formativi executive in istituzioni di rilievo. La nomina punta a sfruttare le nuove opportunità derivanti dai recenti progressi scientifici nelle terapie veicolate da anticorpi.
Defence Therapeutics (OTCQB: DTCFF), una compañía biotecnológica centrada en tecnologías de administración de fármacos, ha designado a la Dra. Amie Phinney como asesora de Estrategia y Negocios. La Dra. Phinney aporta más de 20 años de experiencia en I+D farmacéutica e innovación biotech, habiendo desempeñado puestos clave en Abbott, AbbVie y Solvay Pharmaceuticals.
Su amplia trayectoria incluye cargos como Chief Scientific Officer en Lakeside Discovery y Senior Director of Partnerships en adMare BioInnovations. Posee un doctorado en Investigación Biomédica y un MBA, además de formación ejecutiva en instituciones de prestigio. La incorporación busca aprovechar nuevas oportunidades surgidas de los recientes avances científicos en terapias administradas mediante anticuerpos.
Defence Therapeutics (OTCQB: DTCFF)는 약물 전달 기술을 전문으로 하는 바이오테크 회사로, Amie Phinney 박사를 전략 및 비즈니스 어드바이저로 임명했습니다. Phinney 박사는 애보트(Abbott), 애브비(AbbVie), 솔베이 파마슈티컬스(Solvay Pharmaceuticals) 등에서 핵심 역할을 수행하며 20년 이상의 제약 연구개발 및 바이오 혁신 경험을 쌓았습니다.
그녀는 Lakeside Discovery의 최고과학책임자(CSO)와 adMare BioInnovations의 파트너십 수석 이사(Senior Director of Partnerships) 등을 역임했습니다. 생의학 연구 박사 학위와 MBA를 보유하고 있으며, 저명 기관에서 추가적인 경영자 교육을 받았습니다. 이번 임명은 항체 기반 약물 전달 분야의 최근 과학적 진전이 열어주는 새로운 기회를 활용하기 위한 것입니다.
Defence Therapeutics (OTCQB: DTCFF), une société de biotechnologie spécialisée dans les technologies d'administration de médicaments, a nommé la Dr Amie Phinney au poste de Strategy & Business Advisor. La Dre Phinney apporte plus de 20 ans d'expérience en R&D pharmaceutique et en innovation biotech, ayant occupé des postes clés chez Abbott, AbbVie et Solvay Pharmaceuticals.
Parmi ses fonctions précédentes figurent Chief Scientific Officer chez Lakeside Discovery et Senior Director of Partnerships chez adMare BioInnovations. Elle est titulaire d'un doctorat en recherche biomédicale et d'un MBA, ainsi que de formations exécutives dans des institutions de renom. Cette nomination vise à permettre à Defence Therapeutics de tirer parti des nouvelles opportunités offertes par les récents progrès scientifiques dans les thérapies délivrées par anticorps.
Defence Therapeutics (OTCQB: DTCFF), ein Biotechnologieunternehmen mit Schwerpunkt auf Medikamentenlieferungstechnologien, hat Dr. Amie Phinney zur Strategy & Business Advisor ernannt. Dr. Phinney verfügt über mehr als 20 Jahre Erfahrung in der pharmazeutischen F&E und Biotech-Innovation und bekleidete bedeutende Positionen bei Abbott, AbbVie und Solvay Pharmaceuticals.
Zu ihrem umfangreichen Hintergrund gehören Funktionen als Chief Scientific Officer bei Lakeside Discovery und Senior Director of Partnerships bei adMare BioInnovations. Sie hat einen PhD in biomedizinischer Forschung sowie einen MBA und absolvierte zusätzliche Executive-Weiterbildungen an renommierten Institutionen. Mit der Ernennung soll Defence Therapeutics die sich aus den jüngsten wissenschaftlichen Fortschritten bei antikörpervermittelten Therapien ergebenden Chancen nutzen.
- Strategic appointment of experienced pharma executive with 20+ years in R&D and business development
- Addition of expertise in venture capital and biotech innovation to guide company growth
- Enhancement of leadership team with international pharmaceutical industry experience
- None.
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately. Dr. Phinney will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues exciting new directions emerging from recent scientific advances.
Dr. Phinney is a recognized leader in life sciences commercialization with more than 20 years of experience spanning pharmaceutical R&D, biotech innovation, and strategic ecosystem development. She has held various roles at Abbott and AbbVie Pharmaceutical companies in the USA, directing alliances, leading strategic planning, and business operations across global R&D. Earlier in her career, she held scientific leadership roles at Solvay Pharmaceuticals in Europe, advancing multiple preclinical programs into clinical development.
She went on to serve as Chief Scientific Officer at Lakeside Discovery, a venture-capital backed alliance between Northwestern University and Deerfield Management that advances early-stage therapeutic programs. More recently, as Senior Director of Partnerships and Business Development at adMare BioInnovations, where she supported the creation of multiple biotech ventures emerging from Canadian academia. She brings entrepreneurial experience as a co-founder of Block Biosciences Inc. and Discovery-2-Innovation Life Sciences Consulting, through which she has guided numerous biotech start-ups and academic groups in both the USA and Canada.
"We are at a pivotal point in our company's journey, as our science opens new and transformative opportunities," said Sébastien Plouffe, founder and CEO of Defence Therapeutics. "Amie's exceptional track record - in both scientific and strategic leadership at international pharma companies as well as venture-backed start-ups - will help ensure we capture this momentum and position Defence's for sustainable growth."
"I am thrilled to join Defence Therapeutics in shaping its strategic path forward," said Dr. Phinney. "Their science is breaking new ground and is poised to be transformative to the field of antibody-delivered therapeutics. I look forward to working with the leadership team to build a roadmap that translates these discoveries into innovations that will have long-term impact for Defence's patients, partners, and shareholders."
Dr. Phinney holds a PhD in Biomedical Research from the University of Basel, Switzerland, and an MBA from Lake Forest Graduate School of Management in Chicago, USA. She has also completed executive training in governance, private capital investment, and leadership at the University of Toronto Rotman School of Management, Ivey Business School, and Northwestern's Kellogg School of Management.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264605
FAQ
Who is Dr. Amie Phinney and what is her new role at Defence Therapeutics (DTCFF)?
What experience does Dr. Phinney bring to Defence Therapeutics (DTCFF)?
How will Dr. Phinney's appointment impact Defence Therapeutics' business strategy?
What is Defence Therapeutics (DTCFF) current focus in biotechnology?
